Currently, there are 2.04B common shares owned by the public and among those 2.04B shares have been available to trade.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The company’s stock has a 5-day price change of 0.18% and 11.94% over the past three months. GSK shares are trading 13.63% year to date (YTD), with the 12-month market performance down to -8.28% lower. It has a 12-month low price of $31.72 and touched a high of $45.92 over the same period. GSK has an average intraday trading volume of 4.63 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.26%, 9.48%, and 0.04% respectively.
Institutional ownership of GSK Plc ADR (NYSE: GSK) shares accounts for 16.82% of the company’s 2.04B shares outstanding.
It has a market capitalization of $78.40B and a beta (3y monthly) value of 0.59. The stock’s trailing 12-month PE ratio is 24.29, while the earnings-per-share (ttm) stands at $1.58. The company has a PEG of 3.08 and a Quick Ratio of 0.52 with the debt-to-equity ratio at 1.24. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.52% over the week and 1.67% over the month.
Earnings per share for the fiscal year are expected to increase by 5.19%, and 11.13% over the next financial year. EPS should grow at an annualized rate of 7.89% over the next five years, compared to -11.63% over the past 5-year period.
UBS on their part issued Neutral rating on July 08, 2024.
